Skyrizi vs Entyvio for Crohn's Disease: A Patient Guide

Skyrizi and Entyvio are two non-anti-TNF biologics for moderate-to-severe Crohn's disease, and they take very different approaches to quieting gut inflammation. Skyrizi is an IL-23 p19-selective biologic that acts on the immune system more broadly while still avoiding TNF blockade. Entyvio is gut-selective and acts almost exclusively on the intestines. Both are increasingly common choices for patients who have failed an anti-TNF or want to avoid systemic immunosuppression from the start. This guide walks through the evidence Crohn's patients need for the skyrizi vs entyvio crohn's decision.

IL-23 p19 vs Gut-Selective Mechanism

Skyrizi (risankizumab) binds the p19 subunit of interleukin-23, blocking a cytokine that drives the Th17 inflammatory pathway in Crohn's. Its immune effects are systemic, but they are narrower than anti-TNF or IL-12/23 blockade because only IL-23 is targeted. Entyvio (vedolizumab) binds the alpha-4-beta-7 integrin, a receptor found almost exclusively on gut-homing lymphocytes. By blocking these cells from entering inflamed intestinal tissue, it quiets gut inflammation without meaningfully suppressing the immune system elsewhere. The risankizumab vs vedolizumab distinction matters because mechanism shapes both how fast each drug works and how it performs in different patient populations.

Efficacy in Crohn's

Skyrizi's Crohn's efficacy rests on ADVANCE and MOTIVATE, which showed clinical response and endoscopic improvement at week 12 in both biologic-naive and anti-TNF experienced patients. Entyvio's Crohn's data comes from the GEMINI 2 and GEMINI 3 trials, which showed modest early response compared with placebo and improved outcomes with ongoing maintenance therapy. No head-to-head trial has directly compared Skyrizi with Entyvio in Crohn's. Indirect network meta-analyses suggest Skyrizi produces higher clinical remission rates, particularly in anti-TNF experienced patients, while Entyvio's maintenance data shows durable remission rates when patients have achieved response. For biologic-naive patients, both drugs are reasonable options with somewhat different efficacy profiles.

Onset of Action

Skyrizi tends to work faster than Entyvio in Crohn's. Meaningful clinical improvement with Skyrizi is often evident by week 4, with full response by week 12. Entyvio's label instructs clinicians to wait until week 14 before deciding whether the drug is working, and some patients continue to improve through week 26. For Crohn's patients with active symptoms who need a shorter assessment window, Skyrizi's faster onset is often an advantage. For patients in a less acute state or those with concerns about systemic immunosuppression, Entyvio's slower onset is generally manageable.

Safety and Infection Risk

Both drugs have favorable safety profiles relative to anti-TNFs, but the risk signals differ slightly. Entyvio's gut-selective action produces very low rates of systemic infection, and its long-term safety data is among the cleanest of any IBD biologic for non-GI infections. A 2024 Swedish registry study flagged a higher rate of serious gastrointestinal infections on vedolizumab compared with anti-TNFs, while overall systemic infection risk was lower. Skyrizi's safety profile has been favorable in both Crohn's and psoriasis data, with low rates of serious infections across long-term extensions. For non-TNF biologics crohn's comparisons, both drugs offer meaningful safety advantages over anti-TNFs, with Entyvio having the narrowest immune footprint and Skyrizi having stronger efficacy in anti-TNF experienced populations.

Dosing and Administration

Skyrizi for Crohn's uses IV induction at weeks 0, 4, and 8 (600 mg per infusion), followed by 360 mg subcutaneous every 8 weeks. Entyvio starts with three 300 mg IV infusions at weeks 0, 2, and 6, followed by maintenance every 8 weeks. After IV induction, Entyvio patients who respond by week 6 can switch to a 108 mg subcutaneous pen every 2 weeks, according to Takeda's dosing information. For Crohn's patients who want to minimize long-term infusion visits, both drugs offer SC maintenance options. Skyrizi's every-8-week SC dosing is less frequent than Entyvio's every-2-weeks SC maintenance, which matters for patients who strongly prefer fewer injections over the long term.

Anti-TNF Experienced Patients

For Crohn's patients who have already failed an anti-TNF, MOTIVATE specifically demonstrated Skyrizi's efficacy in this population with meaningful endoscopic response rates. Entyvio has data in anti-TNF experienced patients as well, though response rates are lower than in biologic-naive populations. The SEQUENCE trial showed Skyrizi superior to Stelara in anti-TNF experienced Crohn's, adding to the evidence base supporting Skyrizi in this population. For patients who have cycled through one anti-TNF and are choosing between Skyrizi and Entyvio, trial data tends to favor Skyrizi on efficacy, while Entyvio offers the cleanest systemic safety profile.

Choosing With Your GI

For a Crohn's patient choosing between Skyrizi and Entyvio, both drugs offer meaningful advantages over anti-TNFs. Skyrizi tends to win on speed of onset, clinical remission rates, and efficacy in anti-TNF experienced patients. Entyvio tends to win on the narrowest systemic safety footprint and has the option to convert to SC injections every 2 weeks after IV induction. Your GI will weigh disease severity, prior biologic exposure, comorbidities, and insurance coverage. Before starting either drug, ask how response will be measured after induction (week 12 for Skyrizi, week 14 for Entyvio), what to do if symptoms persist, and whether therapeutic drug monitoring will be part of your plan. A log of stool frequency, urgency, abdominal pain, and any new symptoms between visits helps your care team recognize early loss of response before a full flare returns.